Nichols & Pratt Advisers LLP MA Sells 15,285 Shares of Medtronic PLC $MDT

Key Points

• Nichols & Pratt Advisers LLP MA reduced its Medtronic stake by 9.8%, selling 15,285 shares and retaining 141,131 shares valued at approximately $11.04 million. Institutional investors collectively own 82.06% of the company.
• Medtronic beat quarterly expectations with $1.55 in EPS and $9.81 billion in revenue, while revenue rose 9.9% year over year. The company also announced a quarterly dividend of $0.72, representing a 3.2% yield.
• Analyst sentiment remains broadly positive, with an average “Moderate Buy” rating and a $99.79 target price, though tariff exposure, currency movements and upcoming earnings guidance remain potential risks.

Nichols & Pratt Advisers LLP MA trimmed its stake in shares of Medtronic PLC (NYSE:MDT - Free Report) by 9.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 141,131 shares of the medical technology company's stock after selling 15,285 shares during the period. Nichols & Pratt Advisers LLP MA's holdings in Medtronic were worth $11,041,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MDT. Wedbush Securities Inc. increased its holdings in Medtronic by 5.0% in the 2nd quarter. Wedbush Securities Inc. now owns 52,143 shares of the medical technology company's stock valued at $4,079,000 after acquiring an additional 2,503 shares during the last quarter. Meiji Yasuda Life Insurance Co boosted its holdings in shares of Medtronic by 43.0% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 24,191 shares of the medical technology company's stock valued at $1,892,000 after purchasing an additional 7,278 shares during the last quarter. Thornburg Investment Management Inc. boosted its holdings in shares of Medtronic by 24.5% during the 2nd quarter. Thornburg Investment Management Inc. now owns 2,511,730 shares of the medical technology company's stock valued at $196,493,000 after purchasing an additional 494,653 shares during the last quarter. Hennessy Advisors Inc. grew its position in shares of Medtronic by 50.5% during the second quarter. Hennessy Advisors Inc. now owns 90,326 shares of the medical technology company's stock valued at $7,066,000 after purchasing an additional 30,326 shares in the last quarter. Finally, Sheets Smith Wealth Management purchased a new position in shares of Medtronic during the second quarter valued at about $387,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Medtronic stock opened at $91.28 on Friday. The company's 50-day moving average price is $85.57 and its 200-day moving average price is $85.67. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The company has a market cap of $116.84 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter last year, the firm earned $1.62 EPS. The firm's revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic's dividend payout ratio (DPR) is presently 77.21%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
• Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
• Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
• Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
• Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Rothschild & Co Redburn reduced their target price on Medtronic from $111.00 to $106.00 and set a "buy" rating on the stock in a report on Friday, June 5th. TD Cowen increased their price target on Medtronic from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Friday. Weiss Ratings restated a "hold (c)" rating on shares of Medtronic in a report on Tuesday, August 18th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Finally, JPMorgan Chase & Co. decreased their price objective on Medtronic from $100.00 to $86.00 and set a "neutral" rating on the stock in a report on Thursday, June 4th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Medtronic presently has an average rating of "Moderate Buy" and an average target price of $99.79.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the business's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares of the company's stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.27% of the company's stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source